BlueSphere Bio Appoints Keir Loiacono as Chief Executive Officer
Industry veteran brings nearly 20 years of broad leadership experience in biopharma PITTSBURGH, PA, October 04, 2022 — BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for patients with hematologic malignancies and solid tumors, announced the appointment of Keir Loiacono, Esq. to Chief Executive […]
BlueSphere Bio Appoints Keir Loiacono as Chief Executive Officer Read More »